DGAP-News: Eckert&Ziegler: Bumper year despite a depressive economic mood
(firmenpresse) - Eckert&Ziegler Strahlen- und Medizintechnik AG / Final Results
30.03.2010 10:18
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, March 30, 2010 - The Berlin-based Eckert&Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a specialist for radioactivity in
medicine has tripled its profits in the fiscal year 2009 - and for the
first time was able to overcome the EUR 100 million sales point. Including
special effects the group earned EUR 13.3 million (previous year: EUR 4.5m)
after tax and minority interests in the fiscal year 2009. The profit from
operating activities, i.e. the result excluding special effects increased
from EUR 3.4 million in the previous year by 116% to EUR 7.5 million here
and now. On the basis of an average number of shares amounting to EUR 3.8
million the total annual net profit corresponds to EUR 3.50 per share, the
surplus from operating activities to a sum of EUR 1.97 per share. The
annual sales increased for the sixth successive time to a new record of EUR
101 million (previous year: EUR 72 million, +42%). The Group has thus more
than doubled its sales over the past five years. On average the business
volume has increased by 25% per annum since 2005.
The greatest jump in sales at 74% or EUR 22 million growth was achieved by
the segment Industry where the inclusion of the former competitor Nuclitec
had the greatest impact. The segment Radiopharmacy primarily increased, by
32% to EUR 19 million, by the inclusion of the Yttrium-90 sales of
Nuclitec. The sales of the Russia project of the segment Therapy were only
included at a reduced volume in 2009. Nevertheless, the sales increased by
12% to EUR 30 million.
The segment with the highest yield of the three-division Group in 2009 was
the segment Industry with its components for industrial, scientific and
imaging applications which contributed EUR 1.44 per share or EUR 5.5
million to the annual net profit of the Group. The segment Therapy
contributed (without special effects) towards the consolidated profit EUR
0.30 per share which corresponds to a share of 15%. Without the minority
interests, the result would be EUR 0.56 per share. The segment
Radiopharmacy in which high development expenses burden the result, the
loss compared to the previous year could be greatly reduced to EUR -0.1
million or EUR -0.02 per share. Finally, the Holding registers a profit
before special effects of EUR 0.9 million or EUR 0.25 per share.
The EBIT (Earnings before interest, tax and minorities) adjusted by the
special effects more than doubled, from EUR 6.9 million to EUR 14.6
million.
Balance sheet marked by acquisition and special effects
Deep down, the balance sheet changes can be ascribed to the following
facts: The acquisition of Nuclitec changed the balance sheet compared to
31.12.2008 almost under every single item. The capital increases and the
'Russia Project' led to balance sheet extensions. Thus the cash on the
asset side increased - and on the equity and liabilities side the equity
increased and by the delimitation of the Russia yields also the item
'advance payments received'. The release of accruals from the commitment
surplus of the IBt takeover bid, and the IBt special effectsin connection
with the capitalized deferred taxes, the changes in the goodwill and the
minority shares also markedly influenced the balance sheet. Particularly
due to the capital increases and the annual profit the equity-to-assets
ratio increased from 43% to 54%.
The cash flow from operating activities achieved a new record of EUR 22.1
million which more than doubled compared to the value of 2008. Together
with the revenues from the second capital increase of the year, not yet
invested at the end of the year, the resulting operative capital flow
decisively contributed towards the liquid funds of the Group being
increased by EUR 36.4 million to EUR 43.7 million
The Executive Board and the Supervisory Board will propose an increase in
dividends from Euro 0.30 to EUR 0.45 per share at the Annual General
Meeting convened on 20th May 2010.
For the current year the company expects a result of approx. EUR 1.80 per
share considering an increase of shares by 40%. Without considering the
increased number of shares this would correspond with a growth of some 28%.
With its 520 employees the Eckert&Ziegler Group is one of the largest
global suppliers of isotope technology components for radiotherapy and
nuclear medicine.
Eckert&Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, 13125 Berlin
Phone: +49 (0) 30 / 94 10 84-138, Fax -112, e-mail: karolin.riehle(at)ezag.de,
www.ezag.com
30.03.2010 10:18 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Language: English
Company: Eckert&Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle(at)ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.03.2010 - 04:18 Uhr
Sprache: Deutsch
News-ID 1012180
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 193 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Eckert&Ziegler: Bumper year despite a depressive economic mood
"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert&Ziegler Strahlen- und Medizintechnik AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
